TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02295475
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01211197
Drug: C: BI 10773 / metformin tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
Study: NCT01211197
Drug: B: BI 10773 tablet and metformin tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BI 10773 and metformin single tablets, administered together in fasted state
Study: NCT01211197
Drug: A: BI 10773 / metformin tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BI 10773 / metformin fixed dose combination tablet in fasted state
Study: NCT02977208
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients undergoing chronic treatment with gabapentin are being recruited.
Study: NCT01839500
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab administered in accordance with routine care practice.
Study: NCT02301650
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: mothers use Lamivudine in late pregnancy
Study: NCT02301650
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: mothers use Telbivudine in late pregnancy
Study: NCT02301650
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mothers use Tenofovir in late pregnancy
Study: NCT01756612
Drug: Methoxy Polyethylene Glycol-Epoetin Beta
Normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
Study: NCT03170960
Drug: cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
Study: NCT00516451
Drug: BMS-690514
Normalized name: BMS-690514
DrugBank: BMS-690514 (DB11665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
Study: NCT02683941
Drug: Lanreotide (Autogel formulation)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120mg every 28 days until disease progression, death, or unacceptable toxicity
Study: NCT05189002
Drug: Dimolegin 40 mg
Normalized name: Adagloxad simolenin
DrugBank: Adagloxad simolenin (DB16082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimolegin - DD217 - 40 mg
Study: NCT05189002
Drug: Dimolegin 60 mg
Normalized name: Adagloxad simolenin
DrugBank: Adagloxad simolenin (DB16082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimolegin - DD217 - 60 mg
Study: NCT05189002
Drug: Fragmin
Normalized name: Fragmin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragmin 5000 IU in 0.2 ML Prefilled Syringe
Study: NCT01201863
Drug: Androgel (Testosterone Gel)
Normalized name: testosterone Topical Gel [Androgel]
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
Study: NCT01868568
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin).
Study: NCT01868568
Drug: insulin degludec/insulin aspart 30
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Study: NCT01868568
Drug: insulin degludec/insulin aspart 40
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Study: NCT03170960
Drug: atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
Study: NCT02550665
Drug: donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
Study: NCT01868568
Drug: insulin degludec/insulin aspart 45
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Study: NCT01868568
Drug: insulin degludec/insulin aspart 55
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Study: NCT01868568
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Study: NCT01868568
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose administered subcutaneously (s.c., under the skin).
Study: NCT00587665
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV dose of 0.1 mg/kg of ketamine
Study: NCT04221971
Drug: chemotherapy combined with NK cells infusion
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy combined with NK cells infusion
Study: NCT03170960
Drug: cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
Study: NCT00866723
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00102609
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
Study: NCT00102609
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
Study: NCT03170960
Drug: cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
Study: NCT03908242
Drug: salvianolic acid A
Normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
Study: NCT01657682
Drug: Crenolanib besylate
Normalized name: mesylate
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy.
Study: NCT04876534
Drug: Tocilizumab 20 Mg/mL Intravenous Solution
Normalized name: tocilizumab 20 mg/mL intravenous solution
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration
Study: NCT00714233
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 425mg. capsules, 2 capsules BID x 24 weeks
Study: NCT00714233
Drug: Oral Contraceptive Pills (Yasmin)
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
Study: NCT01272804
Drug: PF-04937319
Normalized name: PF-04937319
DrugBank: PF-04937319 (DB15009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
Study: NCT02730962
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin 3 times a day for 7 days
Study: NCT02730962
Drug: Neomycin
Normalized name: Neomycin
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin 3 times a day for 1 day
Study: NCT00856180
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01894958
Drug: NNZ-2566
Normalized name: NNZ-2591
DrugBank: NNZ-2591 (DB15601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Study: NCT00266318
Drug: Interferon Alfacon-1 and Ribavirin
Normalized name: interferon alfacon-1
DrugBank: Interferon alfacon-1 (DB00069)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00984867
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg tablet, oral, once daily, 48 weeks
Study: NCT01668797
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brexpiprazole tablets 1 to 4 mg /day
Study: NCT00406653
Drug: abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~\~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and \~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months
Study: NCT00406653
Drug: abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: \~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued
Study: NCT01603186
Drug: Quetiapine Fumarate Tablets 25 mg
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablet once a day
Study: NCT01603186
Drug: Quetiapine Fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablet once a day
Study: NCT01004614
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3rd OD 5 mg tablet single oral dose administered with water
Study: NCT01004614
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2nd OD 5 mg tablet single oral dose administered with water
Study: NCT01004614
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3rd OD 5 mg tablet single oral dose administered without water
Study: NCT01004614
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2nd OD 5 mg tablet single oral dose administered without water
Study: NCT01257165
Drug: Zopiclone
Normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zopiclone pill 5 or 10 mg, given orally as a single dose.
Study: NCT03582137
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
Study: NCT00938561
Drug: Inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04865562
Drug: testosterone propionate
Normalized name: Testosterone Propionate
DrugBank: Testosterone propionate (DB01420)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg/0.1mL solution, to be administered intranasally
Study: NCT00483262
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
Study: NCT00558753
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
Study: NCT00377598
Drug: TAK-583
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
Study: NCT00377598
Drug: TAK-583
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
Study: NCT00377598
Drug: TAK-583
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
Study: NCT00377598
Drug: TAK-583
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
Study: NCT02923869
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
Study: NCT02923869
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
Study: NCT00257816
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual.
Study: NCT00257816
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
Study: NCT01210079
Drug: Gabapentin;
Normalized name: Gabapentin;Gabapentin 300 MG; 600 MG Oral Tablet
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
Study: NCT03587194
Drug: Otezla
Normalized name: Otezla
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Otezla 30mg BID
Study: NCT00918190
Drug: Ondansetron, Dexamethasone
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of ondansetron and dexamethasone as combined antiemetics
Study: NCT00918190
Drug: Midazolam, dexamethasone
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: use of midazolam and dexamethasone as combined antiemetic
Study: NCT00530777
Drug: valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
Study: NCT03722576
Drug: Vidofludimus calcium
Normalized name: Vidofludimus
DrugBank: Vidofludimus (DB15446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
Study: NCT03944304
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
Study: NCT00602160
Drug: FAHF-2 (TM)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy.
Study: NCT00151619
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03382821
Drug: Dexamethasone Sodium Phosphate 10 MG/ML
Normalized name: dexamethasone sodium phosphate 10 mg/mL INJECTION KIT
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
Study: NCT03382821
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
Study: NCT03382821
Drug: Triamcinolone Acetonide 40mg/mL
Normalized name: TRIAMCINOLONE ACETONIDE 40MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
Study: NCT03354533
Drug: L-fucose
Normalized name: L-FUCOSE
DrugBank: Fucose (DB15236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ORL-1F
Study: NCT00037700
Drug: anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01675778
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a fixed dose (1 mg) of hydromorphone will be given to the study subjects
Study: NCT00037700
Drug: pegsunercept
Normalized name: Pegsunercept
DrugBank: Pegsunercept (DB06611)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00658099
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Study: NCT00599677
Drug: Itopride
Normalized name: itopride
DrugBank: Itopride (DB04924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
Study: NCT02668185
Drug: NK3R antagonist - AZD4901
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neurokinin 3 receptor antagonist
Study: NCT00066989
Drug: Staphylococcus aureus Immune Globulin (Human) 5%
DrugBank: Staphylococcus aureus immune globulin (human) (DB17755)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02092324
Drug: Ruxolitinib Phosphate
Normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00333385
Drug: ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00167960
Drug: Piperacillin/tazobactam and other β-lactam/β-lactamase
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01145755
Drug: AZD2066
Normalized name: AZD2066
DrugBank: AZD2066 (DB17078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg once daily
Study: NCT00626639
Drug: palifermin
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by intravenous (IV) bolus injection
Study: NCT00626639
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m\^2 intravenously (IV) on days 1, 22 and 43.
Study: NCT01145755
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg once daily
Study: NCT00827567
Drug: RAD 001
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD 001-10 mg by mouth once everyday
Study: NCT03357757
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
Study: NCT02020941
Drug: carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02020941
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT04390464
Drug: Ravulizumab
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to terminal complement protein C5 and prevents the complement-mediated destruction of cells. It is administered by intravenous infusion. Ravulizumab has a marketing authorisation in the UK for treating Paroxysmal Nocturnal Haemoglobinuria in adults.
Study: NCT02164383
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week starter kit of nicotine patch
Study: NCT02525068
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Until confirmed disease progression.